Oragenics, Inc.
OGENAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Goldman Sachs | maintain | Neutral | Jun 3, 2021 |
| H.C. Wainwright | downgrade | Buy →Neutral | Apr 16, 2020 |
| UBS | maintain | Neutral | Nov 15, 2019 |
| H.C. Wainwright | maintain | Buy | Apr 26, 2019 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-90.00| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.57 | $-90.00 | — | — |
| May 8, 2026 | $-0.51 | $-90.00 | — | — |
| Feb 26, 2026 | $-0.54 | $-90.00 | — | — |
| Nov 7, 2025 | $-1.96 | $-144.00 | — | — |
| Aug 8, 2025 | $-3.10 | — | — | — |
| May 9, 2025 | $-3.60 | — | — | — |
| Mar 14, 2025 | $-3.30 | — | — | — |
| Nov 13, 2024 | $-11.41 | $-90.00 | $100.0K | — |
News
Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026 Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical devel…
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status.
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 24,280 shares. The stock had previously closed at $0.5480. Oragenics Trading